Otsuka (OTCMKTS:OTSKY) Shares Gap Up – Here’s Why

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY)’s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $31.85, but opened at $33.15. Otsuka shares last traded at $33.2362, with a volume of 3,518 shares changing hands.

Analyst Ratings Changes

A number of research firms have weighed in on OTSKY. Zacks Research raised shares of Otsuka from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 31st. The Goldman Sachs Group cut shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a report on Friday, February 27th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Otsuka has a consensus rating of “Hold”.

Otsuka Price Performance

The firm has a market capitalization of $35.77 billion and a PE ratio of 14.05. The stock has a 50-day moving average price of $34.60 and a 200 day moving average price of $32.34. The company has a quick ratio of 1.67, a current ratio of 2.17 and a debt-to-equity ratio of 0.05.

Otsuka (OTCMKTS:OTSKY) last posted its quarterly earnings data on Tuesday, April 28th. The company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.43 by $0.16. The business had revenue of $3.96 billion during the quarter, compared to analysts’ expectations of $3.78 billion. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. Equities analysts forecast that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.98 EPS for the current fiscal year.

Otsuka Company Profile

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.